Explosive new research uncovers alarming safety signals and efficacy doubts, challenging the global rollout of mRNA COVID-19 vaccines.

A comprehensive two-part review published in the International Journal of Vaccine Theory, Practice, and Research has raised alarming questions about the safety and efficacy of mRNA COVID-19 vaccines. The papers, titled "COVID-19 Modified mRNA 'Vaccines': Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex" (Parts 1 and 2), present a scathing critique of the clinical trials, regulatory process, and subsequent rollout of these novel vaccines.

Flawed Clinical Trials

The authors argue that the pivotal clinical trials for the Pfizer and Moderna vaccines were fundamentally flawed in both design and execution. They note that the trials were prematurely terminated after only a few months, preventing proper assessment of long-term safety:

"The premature termination of both trials obviated any reliable assessment of potential adverse events due to an insufficient timeframe for proper safety evaluation."¹

Moreover, the researchers contend that many key findings were either misreported or omitted entirely from published trial reports. They highlight a forensic analysis of Pfizer's six-month trial data which revealed concerning patterns:

"Michels et al. (2023) found evidence of a substantial increase in the number of deaths due to cardiovascular events in BNT162b2 recipients that Pfizer did not report... The forensic analysis revealed that 75% of the deaths in modmRNA subjects and 33.3% of those in the placebo group were cardiac-related."¹

Questionable Efficacy Claims

The study casts doubt on the widely touted 95% efficacy rate reported for the vaccines. The authors argue that this figure was based on relative risk reduction, which can be misleading:

"In contrast with the 95% relative risk figure, the absolute risk reductions for BNT162b2 and mRNA-1273 were 0.7% and 1.1%, respectively."¹

They further note that the trials were not designed to assess the vaccines' ability to prevent severe disease, hospitalization, or death - outcomes that were assumed based on reduction of mild symptoms.

Serious Safety Signals

Perhaps most alarmingly, the researchers present evidence suggesting the vaccines may be causing significant harm. They cite a re-analysis of the trial data by Fraiman et al. which found:

"For both the Pfizer and Moderna trials combined, there were about 125 serious adverse events per 100,000 modmRNA recipients, which translates into one serious adverse event for every 800 modmRNA recipients."¹

The authors argue that post-marketing surveillance has revealed even more concerning safety signals, referencing a confidential Pfizer document that reported:

"1.6 million adverse events covering nearly every organ system in the human body... One-third of the adverse events were classified as serious."¹

Calls for Moratorium

In light of these findings, the study's authors make a bold recommendation:

"We urge governments to endorse and enforce a global moratorium on these modmRNA products and the lipid nanoparticle delivery platform, unless and until all relevant questions pertaining to causality, residual DNA, and aberrant protein production are resolved."¹

This extensive review raises serious questions about the mRNA COVID-19 vaccines that have been administered to billions of people worldwide. While the vaccines have been credited with reducing COVID-19 severity and deaths by health authorities, this study suggests their risk-benefit profile may be far less favorable than previously believed.

As the scientific community continues to debate these issues, this paper is likely to fuel further controversy and calls for additional investigation into the long-term effects of this novel vaccine technology.

Learn more about COVID-19 on our database dedicated to the topic here.

Learn more about COVID-19 vaccinations on our database here.

References

1. Mead, M. Nathaniel, Stephanie Seneff, Russ Wolfinger, Jessica Rose, Kris Denhaerynck, Steve Kirsch, and Peter A. McCullough. "COVID-19 Modified mRNA 'Vaccines': Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1." International Journal of Vaccine Theory, Practice, and Research 3, no. 2 (2024): 1112-1178.